Method and composition for treatment of skin diseases associated with accelerated corneodesmosomes degradation or weaker cell-cell adhesion

Patent metadata

Field	Value
Publication number	US-12544386-B2
Application number	US-202017610276-A
Country	US
Kind code	B2
Filing date	May 13, 2020
Priority date	May 15, 2019
Publication date	Feb 10, 2026
Grant date	Feb 10, 2026

Abstract

The present invention provides a method and a pharmaceutical composition for treatment of skin diseases associated with accelerated comeodesmosomes degradation and/or weaker cell-cell adhesion, such as a peeling skin syndrome, Netherton syndrome, and atopic dermatitis.

First claim

The invention claimed is:

1 . A method for treatment of a skin disease or disorder associated with accelerated corneodesmosomes degradation and/or weaker cell-cell adhesion in a subject in need thereof, comprising administering/applying to the skin of said subject a topical pharmaceutical composition comprising a topically acceptable oily carrier and a therapeutically effective amount of an active agent selected from the group consisting of betulinic acid and a pharmaceutically acceptable salt, ester, or amide thereof, wherein said skin disease or disorder is peeling skin syndrome (PSS).

2 . The method of claim 1 , wherein said active agent is betulinic acid or a pharmaceutically acceptable salt thereof.

3 . The method of claim 1 , wherein said active agent is betulinic acid ester.

4 . The method of claim 1 , wherein said active agent is betulinic acid amide.

5 . The method of claim 1 , wherein said topical pharmaceutical composition is administered to one or more sites on the subject's skin.

6 . The method of claim 1 , wherein said topical pharmaceutical composition is administered once, twice, or thrice a day.

7 . The method of claim 1 , wherein said topical pharmaceutical composition is formulated as an ointment, salve, cream, paste, lotion, or oil-in-water emulsion.

8 . The method of claim 7 , wherein said topically acceptable oily carrier comprises at least one viscosity-modifying agent.

9 . The method of claim 8 , wherein said topically acceptable oily carrier comprises a paraffin oil and white petroleum.

10 . The method of claim 7 , wherein said topical pharmaceutical composition comprises up to about 20%, by weight, of said active agent.

11 . The method of claim 1 , wherein said subject does not suffer from epidermolysis bullosa, or from melanoma.

12 . The method of claim 8 , wherein said viscosity-modifying agent is a mineral oil or a surfactant.

13 . The method of claim 11 , wherein said epidermolysis bullosa is dystrophic epidermolysis bullosa or junctional epidermolysis bullosa, and said melanoma is cutaneous metastatic melanoma.

14 . The method of claim 1 , wherein said peeling skin syndrome (PSS) is noninflammatory PSS, inflammatory PSS, or acral PSS.

15 . The method of claim 1 , wherein said topical pharmaceutical composition is formulated as an ointment, and said active agent is betulinic acid.

16 . The method of claim 15 , wherein said PSS is noninflammatory PSS.

Assignees

• Ichilov Tech Ltd
• Univ Ramot

Inventors

• Sprecher Eli
• Sarig Ofer
• Mohamad Janan
• Peled Alon

Classifications

• A61K47/06

  Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite · CPC title

• A61K9/0014 Primary

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K31/215

  of carboxylic acids · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title